A phase I/II dose schedule finding study of ch14.18/CHO continuous infusion combined with subcutaneous Aldesleukin (IL-2) in patients with primary refractory or relapsed Neuroblastoma
Phase of Trial: Phase I/II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Dinutuximab beta (Primary) ; Aldesleukin; Isotretinoin
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2016 Interim results (n=124) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 29 Mar 2016 Accrual to date is 12% according to United Kingdom Clinical Research Network record.
- 05 Oct 2015 Accrual to date is 10% according to United Kingdom Clinical Research Network record.